Cover Image
市場調查報告書

第二型神經纖維瘤 (NF2):開發中產品分析

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 277753
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
第二型神經纖維瘤 (NF2):開發中產品分析 Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline Review, H1 2017
出版日期: 2017年06月27日 內容資訊: 英文 49 Pages
簡介

所謂第二型神經纖維瘤(NF2)是以神經系統非癌性腫瘤之增殖為特徵的一種疾病。沿著內耳到腦(聽覺神經)的情報運輸神經發症。其他神經產生的腫瘤最常以這種狀態發現。主要的症狀有聽障、耳鳴、平衡感異常等。

本報告提供第二型神經纖維瘤 (NF2) 的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

第二型神經纖維瘤概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

第二型神經纖維瘤:企業開發中的治療藥

第二型神經纖維瘤:大學/機關研究中的治療藥

第二型神經纖維瘤:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

第二型神經纖維瘤:企業開發中的產品

第二型神經纖維瘤:大學/機關研究中的產品

第二型神經纖維瘤的治療藥的開發企業

  • Arno Therapeutics, Inc.
  • CalAsia Pharmaceuticals, Inc.
  • Lixte Biotechnology Holdings, Inc.
  • Novartis AG

第二型神經纖維瘤:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

第二型神經纖維瘤:最近的開發平台趨勢

第二型神經纖維瘤:暫停中的計劃

第二型神經纖維瘤:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9434IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline Review, H1 2017, provides an overview of the Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) pipeline landscape.

Neurofibromatosis type 1 (NF1), also called von Recklinghausen's disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses Type I (Von Recklinghausen's Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) - Overview
    • Neurofibromatoses Type I (Von Recklinghausen's Disease) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) - Companies Involved in Therapeutics Development
    • Alexion Pharmaceuticals Inc
    • Array BioPharma Inc
    • AstraZeneca Plc
    • Celldex Therapeutics Inc
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) - Drug Profiles
    • asfotase alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • binimetinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CDX-0158 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • selumetinib sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Neurofibromatoses Type I - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen's Disease), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by Alexion Pharmaceuticals Inc, H1 2017
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by Array BioPharma Inc, H1 2017
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by AstraZeneca Plc, H1 2017
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by Celldex Therapeutics Inc, H1 2017
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen's Disease), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top